ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 513

Low Serum IGF1 Is Associated with Higher Cardiovascular Morbidity in the Middle-Aged Women with Rheumatoid Arthritis

Malin C Erlandsson1,2, Lovisa Lyngfelt3, Caroline Wasén3, Sofia Töyrä Silfverswärd3, Mitra Nadali1,3, Rille Pullerits1,3,4 and Maria I Bokarewa1, 1Rheumatology Clinic, Sahlgrenska University Hospital, Gothenburg, Sweden, 2Department of rheumatology and inflammation research, University of Gothenburg, Gothenburg, Sweden, 3Department of Rheumatology, Institute of Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden, 4Department of Clinical immunology and transfusion medicine, Sahlgrenska University Hospital, Gothenburg, Sweden

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, Comorbidity and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Since low serum IGF1 is generally attributed to inflammation and RA severity, we analyze if serum levels of IGF1 is associated with cardiovascular (CV) risk in women with rheumatoid arthritis (RA).

Methods:

The risk of developing of CV disease within 10 years was calculated in a cohort of 184 female RA patients (median age 53 years, range 21-71) with no history of CV events, using the Framingham strategy. A 5-year follow-up of new CV events was completed by a structured interview in all the patients. The reported CV events were confirmed through the Swedish National Patient Register. The CV risk and CV event-free survival curves were compared with respect to serum IGF1 levels, where IGF1 levels below the median of the total cohort were considered low.

Results:

The RA women with low IGF1 (n=96, median 110 pg/ml) had significantly higher CVR compared to those with normal IGF1 (n=88, median 181 pg/ml) with the predicted risk of 7.2 % and 3.3 %, respectively (p<0.001). In age-adjusted groups, CVR was significantly higher in females ≤50 years with low IGF1 (p<0.001). At 5-year follow up, 12 (6.5%) patients experienced CV event. A Kaplan-Meier analysis showed that the CV events occurred with higher frequency in the patients with low IGF1 at baseline (p=0.029). After 5 years the risk of having experienced a cardiovascular event was 5 times higher in patients with low IGF1 at baseline (RR 4.583; CI95% 1.033-20.34; p=0.027). At baseline the IGF1low group had high prevalence of hypertension (24% vs. 8.5%, p=0.004) and higher BMI (p=0.008). The atherogenic index (total cholesterol/HDL) (2.8 vs 3.0) and smoking (15% vs. 14%) was similar between the groups. With exception for disease duration, the groups were similar in RA-related CVR factors as seropositivity (91% vs 92%), disease activity measured by DAS28 (median 3.20 vs 2.90), or systemic inflammation measured by serum IL6 and IL1b. The prevalence of treatment with MTX monotherapy was higher in the IGF1low group (56% vs. 39%, p=0.024), while the use of TNFi and other biologics was similar within the groups.

Conclusion:

Female patients with RA, IGF1 levels in the normal low range are associated with higher CVR and experienced higher frequency of CV events. This increase in CV disease seems to be independent of the RA-related characteristics.


Disclosure: M. C. Erlandsson, None; L. Lyngfelt, None; C. Wasén, None; S. Töyrä Silfverswärd, None; M. Nadali, None; R. Pullerits, None; M. I. Bokarewa, None.

To cite this abstract in AMA style:

Erlandsson MC, Lyngfelt L, Wasén C, Töyrä Silfverswärd S, Nadali M, Pullerits R, Bokarewa MI. Low Serum IGF1 Is Associated with Higher Cardiovascular Morbidity in the Middle-Aged Women with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/low-serum-igf1-is-associated-with-higher-cardiovascular-morbidity-in-the-middle-aged-women-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/low-serum-igf1-is-associated-with-higher-cardiovascular-morbidity-in-the-middle-aged-women-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology